Resolvins: Agonists of Inflammation Resolution
Discovered by researchers at Harvard, Resolvins are a novel class of "Immunoresolvents" that resolve inflammation, enhance clearance of debris (phagocytosis), and promote healing. Unlike traditional anti-inflammatory drugs that inhibit immune function, Resolvins are agonists that regulate innate immunity without compromising host defense.
Acute inflammation in healthy people is normally followed by a resolution phase that returns tissue to homeostasis. Dr. Charles Serhan (Harvard Medical School) and collaborators have demonstrated that inflammation resolution is a highly regulated process coordinated by Specialized Proresolving Mediators (SPMs), a superfamily of eicosanoids that include the Resolvins. Unlike traditional anti-inflammatory drugs that inhibit immune function, Resolvins are agonists that regulate innate immunity without compromising host defense.
Resolvin E1 (RvE1) is one of the most widely investigated SPMs since its discovery 20 years ago. In multiple models of disease, RvE1 has been shown to address key aspects of disease pathophysiology, including downregulation of inflammatory mediators and cytokines (NF-κB, TNF-α, IL-12, IL-6, IL-1β, IFN-γ), increased macrophage-induced uptake of apoptotic cells via phagocytosis/efferocytosis, reduced neutrophil migration, and increased neutrophil apoptosis and tissue repair. Taken together, these pro-resolving properties make SPMs such as RvE1 attractive, non-immunosuppressive candidates for the treatment of immunological and inflammatory disorders.
Despite promising biology, the development of Resolvin-based therapies has been hampered by challenges related to instability and physical-chemical properties. Using our proprietary HEALER technology, we stabilize Resolvins to enable their pharmaceutical development as patent-protected drugs. By leveraging innate biology, our approach has prospects for the safe and effective treatment of many immunological and inflammatory diseases.